New Multiple Sclerosis Clinical Trials at MidAmerica Neuroscience Institute
Posted on Wed, Jul 06, 2011 @ 10:55 AM
Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis
Title: A Randomized, Double Blind, Placebo-Controlled Efficacy and Safety Study of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis
Purpose: To evaluate the efficacy of three doses of XP19986 (arbaclofen placarbil) compared to placebo for the treatment of spasticity in subjects with multiple sclerosis (MS).
http://www.clinicaltrials.gov/ct2/show/NCT01359566?term=xenoport+ms&rank=2
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Title: A Phase III, Multicentre, Randomized, Parallel-group, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis
Purpose: This randomized, parallel group, double-blind, placebo controlled study will evaluate the efficacy and safety of ocrelizumab in patients with primary progressive multiple sclerosis. Eligible patients will be randomized 2 : 1 to receive either ocrelizumab (300 mg intravenously on Days 1 and 15 of the first treatment cycle, followed by 600 mg iv every 24 weeks) or placebo. The blinded treatment period will be at least 120 weeks, followed by open label treatment for patients in both groups who in the opinion of the investigator could benefit from further or newly initiated ocrelizumab treatment. Anticipated time on study treatment is up to 5.5 years.
http://www.clinicaltrials.gov/ct2/show/NCT01194570?term=roche+ms&rank=3
Contact one of our Clinical Research Coordinators for more information or to see if you qualify. 913-894-1500